NVCT
HEALTHCARENuvectis Pharma Inc
$10.00+0.29 (+2.99%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NVCT Today?
No stock-specific AI insight has been generated for NVCT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.55$11.15
$10.00
Fundamentals
Market Cap$265M
P/E Ratio—
EPS$-1.31
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume176K
Avg Volume (10D)—
Shares Outstanding26.5M
NVCT News
20 articles- Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to TradeYahoo Finance·May 7, 2026
- Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 5, 2026
- Insider Stock Buying Reaches US$2.07m On Nuvectis PharmaYahoo Finance·May 4, 2026
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingGlobeNewswire Inc.·Mar 31, 2026
- Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn SituationYahoo Finance·Mar 24, 2026
- Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business HighlightsYahoo Finance·Feb 11, 2026
- Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLCYahoo Finance·Dec 17, 2025
- Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insidersYahoo Finance·Dec 5, 2025
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCYahoo Finance·Nov 25, 2025
- Director of Nuvectis Pharma Juan Sanchez Buys 20% More SharesYahoo Finance·Nov 8, 2025
- CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsYahoo Finance·Nov 4, 2025
- Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsYahoo Finance·Nov 4, 2025
- Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 27, 2025
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 16, 2025
- Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth PlansYahoo Finance·Oct 15, 2025
- Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of DirectorsYahoo Finance·Sep 25, 2025
- Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 4, 2025
- Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900Yahoo Finance·Aug 11, 2025
- Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business HighlightsYahoo Finance·Aug 5, 2025
- Nuvectis Pharma cuts NXP800 in ovarian cancer after early failureClinicaltrialsarena·Aug 4, 2025
All 20 articles loaded
Price Data
Open$8.55
Previous Close$9.71
Day High$8.79
Day Low$8.42
52 Week High$11.15
52 Week Low$5.55
52-Week Range
$5.55$11.15
$10.00
Fundamentals
Market Cap$265M
P/E Ratio—
EPS$-1.31
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume176K
Avg Volume (10D)—
Shares Outstanding26.5M
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. The company is headquartered in Fort Lee, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—